Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Oral Antiviral Therapy for Idiopathic Trigeminal Neuralgia
Sponsor: Beijing Tiantan Hospital
Summary
This is a multicenter, prospective, randomized, controlled trial. A total of 165 patients with idiopathic trigeminal neuralgia will be enrolled and randomly divided into three groups at a 1:1:1 ratio. The aim is to compare the efficacy and safety of conventional carbamazepine monotherapy, carbamazepine combined with oral antiviral therapy, and carbamazepine combined with anti-inflammatory therapy in pain relief, quality of life improvement and adverse event profiles.
Official title: Efficacy and Safety of Oral Antiviral Drug Combined With Carbamazepine Versus Celecoxib Combined With Carbamazepine in the Treatment of Idiopathic Trigeminal Neuralgia: A Multicenter, Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
165
Start Date
2026-08-31
Completion Date
2027-12-31
Last Updated
2026-06-29
Healthy Volunteers
No
Conditions
Interventions
Intervention：Drug: Carbamazepine
ArmA Dosage：Initial dose 200 mg daily, titrated gradually to maximum 600 mg daily, divided into 2-3 times per day for 12 weeks.
Intervention：Drug: Carbamazepine + Acyclovir
ArmB Dosage：Carbamazepine 200-600 mg/d; Acyclovir 800 mg three times daily for 12 weeks.
Intervention：Drug: Carbamazepine + Celecoxib
Dosage：Carbamazepine 200-600 mg/d; Celecoxib 200 mg twice daily for 12 weeks.